Annual Accounts Receivable
$200.00 M
+$200.00 M+100.00%
31 December 2023
Summary:
CRISPR Therapeutics AG annual accounts receivable is currently $200.00 million, with the most recent change of +$200.00 million (+100.00%) on 31 December 2023. During the last 3 years, it has risen by +$199.86 million (+138788.89%). CRSP annual accounts receivable is now at all-time high.CRSP Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$0.00
$0.000.00%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly accounts receivable is currently $0.00, unchanged on 30 September 2024. CRSP quarterly accounts receivable is now -100.00% below its all-time high of $200.00 million, reached on 31 December 2023.CRSP Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.0% | - |
| 3 y3 years | +10000.0% | -100.0% |
| 5 y5 years | +10000.0% | -100.0% |
CRSP Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | -100.0% | ||
| 5 y | 5 years | at high | -100.0% | ||
| alltime | all time | at high | -100.0% |
CRISPR Therapeutics AG Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $0.00(0.0%) |
| June 2024 | - | $0.00(0.0%) |
| Mar 2024 | - | $0.00(-100.0%) |
| Dec 2023 | $200.00 M(>+9900.0%) | $200.00 M(+185.7%) |
| June 2023 | - | $70.00 M(>+9900.0%) |
| Dec 2022 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sept 2022 | - | $49.00 K(-25.8%) |
| June 2022 | - | $66.00 K(-53.8%) |
| Mar 2022 | - | $143.00 K(-53.1%) |
| Dec 2021 | $305.00 K(+111.8%) | $305.00 K(+100.7%) |
| Sept 2021 | - | $152.00 K(+1.3%) |
| June 2021 | - | $150.00 K(0.0%) |
| Mar 2021 | - | $150.00 K(+4.2%) |
| Dec 2020 | $144.00 K | $144.00 K(+30.9%) |
| Sept 2020 | - | $110.00 K(+233.3%) |
| June 2020 | - | $33.00 K(-99.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $25.12 M(>+9900.0%) |
| Dec 2019 | $99.00 K(+12.5%) | $99.00 K(+153.8%) |
| Sept 2019 | - | $39.00 K(-87.9%) |
| June 2019 | - | $321.00 K(-3.0%) |
| Mar 2019 | - | $331.00 K(+276.1%) |
| Dec 2018 | $88.00 K(-96.6%) | $88.00 K(-84.1%) |
| Sept 2018 | - | $552.00 K(-41.5%) |
| June 2018 | - | $944.00 K(-25.1%) |
| Mar 2018 | - | $1.26 M(-52.0%) |
| Dec 2017 | $2.63 M(-16.8%) | $2.63 M(-18.2%) |
| Sept 2017 | - | $3.21 M(-52.9%) |
| June 2017 | - | $6.81 M(+20.1%) |
| Mar 2017 | - | $5.67 M(+79.7%) |
| Dec 2016 | $3.16 M(+831.3%) | $3.16 M(+50.9%) |
| Sept 2016 | - | $2.09 M(+54.5%) |
| June 2016 | - | $1.35 M(+299.4%) |
| Dec 2015 | $339.00 K | $339.00 K |
FAQ
- What is CRISPR Therapeutics AG annual accounts receivable?
- What is the all time high annual accounts receivable for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual accounts receivable year-on-year change?
- What is CRISPR Therapeutics AG quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for CRISPR Therapeutics AG?
What is CRISPR Therapeutics AG annual accounts receivable?
The current annual accounts receivable of CRSP is $200.00 M
What is the all time high annual accounts receivable for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual accounts receivable is $200.00 M
What is CRISPR Therapeutics AG annual accounts receivable year-on-year change?
Over the past year, CRSP annual accounts receivable has changed by +$200.00 M (+100.00%)
What is CRISPR Therapeutics AG quarterly accounts receivable?
The current quarterly accounts receivable of CRSP is $0.00
What is the all time high quarterly accounts receivable for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly accounts receivable is $200.00 M